Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Tivantinib stomach carcinoma not applicable detail...
MET amp MET over exp K252a stomach carcinoma sensitive detail...
MET act mut S-49076 stomach carcinoma sensitive detail...
FGFR2 act mut S-49076 stomach carcinoma sensitive detail...
ERBB2 positive Tucatinib stomach carcinoma sensitive detail...
CDKN2A R80* Palbociclib stomach carcinoma sensitive detail...
Unknown unknown SST0116CL1 stomach carcinoma not applicable detail...
MET amp EMD 1214063 stomach carcinoma sensitive detail...
ERBB2 positive SYD985 stomach carcinoma sensitive detail...
FGFR2 amp PRN1371 stomach carcinoma sensitive detail...
FGFR2 amp RO4987655 stomach carcinoma no benefit detail...
FGFR2 amp RO5126766 stomach carcinoma no benefit detail...
ERBB2 amp Debio 1347 stomach carcinoma no benefit detail...
FGFR2 amp Debio 1347 stomach carcinoma sensitive detail...
Unknown unknown MGCD516 stomach carcinoma not applicable detail...
MET over exp EMD 1214063 stomach carcinoma sensitive detail...
MET over exp TP53 dec exp EMD 1214063 + Radiotherapy stomach carcinoma sensitive detail...
BRAF mutant KO-947 stomach carcinoma predicted - sensitive detail...
NRAS mutant KO-947 stomach carcinoma predicted - sensitive detail...
MET del exon14 SAIT301 stomach carcinoma sensitive detail...
MET del exon14 Crizotinib stomach carcinoma sensitive detail...
MET del exon14 PHA-665752 stomach carcinoma sensitive detail...
MET del exon14 Cabozantinib stomach carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
NCT01183559 Phase I Carboplatin + Fluorouracil + Paclitaxel + Vandetanib A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery Unknown status
NCT02065765 Phase II Ramucirumab International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer No longer available
NCT02274012 Phase II Afatinib + Paclitaxel Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer Withdrawn
NCT02344810 Phase Ib/II AMG 337 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Withdrawn
NCT02488759 Phase Ib/II Nivolumab A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) Recruiting
NCT02773524 Phase III Regorafenib A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEII) Recruiting
NCT02830594 Phase II Pembrolizumab Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer Recruiting
NCT02892123 Phase I Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 Trial of ZW25 in Patients With Advanced HER2-expressing Cancers Recruiting
NCT03008278 Phase Ib/II Olaparib + Ramucirumab Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Recruiting
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Recruiting
NCT03175224 Phase I CBT-101 CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation Recruiting
NCT03288350 Phase II Cisplatin + Docetaxel + Fluorouracil Avelumab mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA) Recruiting
NCT03474640 Phase I JS001 Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies Recruiting